A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen
Status:
Withdrawn
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, study to compare Iodine I 131 Tositumomab therapeutic
regimen to Ibritumomab Tiuxetan therapeutic regimen in the treatment of patients with
relapsed or transformed follicular non-Hodgkin's B-cell lymphoma. A total of 350 patients,
approximately 175 patients per arm, will be enrolled at 30 to 40 sites in the United States.